Polatuzumab vedotin

Polatuzumab vedotin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Hodgkin Lymphoma、B-Cell Lymphoma、Relapsed B-cell NHL、Recurrent Grade 1 Follicular Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Polatuzumab vedotin 研究

• Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

  II 期招募中奥地利比利时CroatiaCzechiaNCT04844866

• Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas

  II 期招募中RussiaNCT07883135

• Pola-ZR2P in Previously Untreated DLBCL

  II 期招募中中国NCT06664411

• Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

  II 期招募中中国NCT07499271

• The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma

  III 期招募中中国NCT06522555

• CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

  II 期招募中美国NCT05260957

• Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

  不适用招募中中国NCT07778212

• Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

  I 期招募中美国NCT06730542

• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

  I 期 / II 期招募中美国NCT04491370

• A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT05800366

• Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

  II 期招募中中国NCT06176729

• Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

  II 期招募中中国NCT07608978

• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  I 期招募中美国NCT06015880

• Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

  II 期招募中美国NCT06453044

• A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

  III 期招募中澳大利亚丹麦芬兰意大利NCT04332822

• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

  II 期招募中英国NCT06071871

• POLA-R-CHP in the First-line Treatment of Transformed DLBCL

  II 期招募中中国NCT06743945

• The CARDIOPROTECT Trial

  II 期招募中美国NCT07654426

• A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

  II 期招募中美国NCT05615636

• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

  II 期招募中美国NCT06043674

• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

  II 期招募中美国NCT06594939

• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  II 期招募中美国NCT05633615

• Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

  II 期招募中加拿大NCT06050694

• Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

  II 期招募中中国NCT07001540

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。